Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Monoclonal Antibodies as Potent Inhibitors of Metalloprotienases
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
Targeting of an inhibitory antibody to the catalytic cleft of metalloenzymesMetalloenzymes are important medicinal targets for conditions ranging from pathogenic infections to cancer. Inhibitory monoclonal antibody (mAb) scaffolds are often used to......
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

Targeting of an inhibitory antibody to the catalytic cleft of metalloenzymes


Metalloenzymes are important medicinal targets for conditions ranging from pathogenic infections to cancer. Inhibitory monoclonal antibody (mAb) scaffolds are often used to achieve selective molecular blocking of various metalloenzyme targets. However, antibodies' potency is often limited by the low immunogenicity of functional sites residing in protein clefts. The present technology consists of a novel approach for generating highly potent and selective inhibitory mAbs (metallobodies) targeting functional metallo-sites.



 


Applications






    • Treatment of inflammatory bowl disease





    • A general strategy in the field of function blocking/therapeutic antibodies targeted at enzyme catalytic metal sites





Advantages






    • This approach enables direct antibody targeting to the enzymatic active site as well as the its surface





    • The antibody recognizes only the active form of the metalloproteinase





Technology's Essence


Specific targeting of inhibitory antibodies to enzymatic active sites is invaluable both for research purposes, and as clinical diagnostic and therapeutic reagents. The innovative immunization strategy implemented in the current technology utilizes smart metallo-site mimicry organic molecules, followed by whole metalloenzyme of interest to stimulate affinity maturation towards metal-ion epitope and additional surface epitopes in the context of the whole molecule. This immunization procedure yielded prototype function blocking metallobodies targeting the catalytic zinc ion in matrix metalloproteinase-9 (MMP-9), an enzyme associated with inflammatory conditions and invasion diseases. As it was estimated that over 30% of known proteins require metal cofactors for proper functionality, this approach may provide a wide range of applications.


Licensing Status

FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION